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STAGE I AND II BREAST CANCERS. Margaret M. Toth, Stuart D. Flynn, and
Bruce G. Haffty. Department of Therapeutic Radiology, Yale University, School of
Medicine, New Haven, CT.

Abstract
Over the past decade, breast conserving surgery with primary radiotherapy has
been frequently employed as an option for the treatment of early breast cancer.

With

increasing follow-up, it is clear conservatively treated patients have a long-term risk for
local recurrence. To date, prognostic indicators following recurrence are limited to
clinical and pathological observations. No objective prognostic parameters have been
established.
The purpose of the research summarized in this thesis was to determine whether
DNA flow cytometry is a useful indicator of prognosis in patients who have suffered
local recurrence following conservative treatment. Archival breast tissue specimens
from tumor recurrences were obtained from 38 of the 50 women in the Yale-New
Haven Hospital series who suffered local failure following conservative treatment.
Median follow-up after recurrence was 5.06 years.
DNA flow cytometric measurements of DNA-ploidy and S-phase fraction were
performed on all available samples.

62% of patients had DNA-diploid recurrent

tumors. DNA-ploidy was predictive of both overall and disease-free survival at five
years (p=0.015 and p=0.028).
predictor of prognosis.

S-phase fraction proved to be a highly significant

35% of patients had low SPF tumors (SPF < 12).

The

probability of disease-free survival five-years post-recurrence was 100% for the low
SPF tumor patients and 32% for patients with high SPF tumors (p=0.00005). DNAploidy and S-phase fraction were combined to define favorable and unfavorable flow
profiles (favorable = DNA-diploid, SPF < 12).

Actuarial disease-free survival five-

years post-recurrence was 100% for patients with a favorable flow profile and 36% for
patients with an unfavorable flow profile (p=0.0002). This data suggests DNA flow
cytometric measurements at relapse strongly correlate with outcome for patients
suffering local recurrence following conservative treatment for early stage breast
cancer.
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THE USE OF DNA FLOW CYTOMETRY AS A PROGNOSTIC
INDICATOR AFTER LOCAL RECURRENCE IN CONSERVATIVELY
TREATED CLINICAL STAGE I AND II BREAST CANCERS.

Introduction

Breast cancer is the most common malignancy among western women with
124,000 new cases reported each year in the United States.1 Although each American
woman has a one in ten risk of developing the disease, early detection of breast lesions
with self-examination and screening mammography appear to have increased the
number of women for whom cure is possible. Currently, a number of local treatment
options, ranging from modified radical mastectomy to breast conserving surgery with
radiation therapy, are available. In addition, systemic chemotherapy can be added to
delay, if not prevent, distant metastases. Rationale and justification for the use of
conservative treatment for early stage breast cancer can be derived from numerous
retrospective as well as prospective studies.211

Patients whose breast cancer has been conservatively treated have a protracted
risk for local recurrence.

Following local recurrence, salvage mastectomy can be

performed offering 59-84% survival at five years.1215 Even though many qualitative

clinical and pathological variables have been associated with prognosis at the time of
local recurrence, quantitative variables are lacking.16 20 DNA flow cytometric (DNAFC) parameters successfully predict prognosis for patients with primary breast
cancer.2130 The research summarized in this thesis investigates the prognostic value
of DNA-FC for women who have experienced local failure following conservative
treatment of stage I and II breast cancers.

TREA TMENT OPTIONS FOR EARL Y BREAST CANCER

Since Roman times, early breast cancer has been considered a local problem
amenable to surgical treatment.

Until recently, the Halsted radical mastectomy,

developed by William Stewart Halsted at the Johns Hopkins Hospital during the
1890’s, has remained the standard treatment for early breast cancer in the United States.
This procedure assumes breast cancer is initially a local disease, and includes surgical
removal of the breast, pectoral fascia, pectoralis major and minor muscles and in most
cases complete axillary dissection. The modified radical mastectomy is now the most
commonly applied technique for breast amputation. In addition to removal of the
cancerous breast, the underlying pectoralis minor muscle, pectoralis fascia and in most
cases draining axillary nodes are removed.

With publication in the mid 1960’s of the first reports of primary breast
irradiation, a new era in breast cancer treatment began.31'34 These early reports of
conservative treatment with limited surgery and primary irradiation were limited to
patients who had either refused a radical mastectomy, were elderly or too ill for surgery
or had locally advanced disease unsuitable for mastectomy.
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The reports were

noteworthy as they demonstrated long term survival was possible for at least some
patients treated with conservative surgery and primary radiotherapy

This led to

experimental trials of conservative treatment and subsequently several definitive
prospective studies in the United States and Europe which have established the efficacy
of conservational surgery with radiation therapy (CS+p°RT) for the treatment of early
breast cancer.

EVIDENCE JUSTIFYING THE USE OF CONSERVATIVE TREATMENT FOR
EARL Y BREAST CANCER

During the last decade, CS+p°RT has been used increasingly for the treatment
of early stage breast cancer. This treatment involves excision of the malignant breast
lesion, preserving the breast’s cosmetic appearance, and departs from the historical
perspective of breast cancer controlled by ablative local surgery. Such removal of the
lesion is followed by definitive irradiation of the involved breast with or without
irradiation of the regional axillary, internal mammary and supraclavicular lymph nodes.

The first studies of conservative treatment for early stage breast cancer were
necessarily retrospective. The largest of these are summarized in table 1. Drawing
conclusions from these studies is hindered by differences in patient selection, mode of
staging, surgical technique, dose of radiation and statistical methods employed. Yet, all
demonstrate disease-free and overall survival following CS+p°RT similar to that
achieved with mastectomy.2
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The Yale-New Haven Hospital experience is typical of the retrospective data
supporting the use of CS+p°RT as an option for the treatment of early stage breast
cancer.5 This series included 433 women treated with CS+p°RT at the Yale-New
Haven Hospital between 1962-1984 of which 70% were clinically stage I and 30%
were stage II. All patients were followed for a minimum of five years.

The conservational surgical technique was limited to excision of local tumor
with a rim of grossly normal tissue, without a specific requirement for microscopically
free surgical margins. Axillary dissections were not routinely performed. Radiation
therapy was defined by tangential fields to the breast with an electron boost to the tumor
bed to a total median tumor dose of 6400 cGy. The regional nodes were treated in the
majority of patients by separate internal mammary and supraclavicular/axillary portals
to a total median dose of 4600 cGy. Most patients did not receive adjuvant systemic
therapy.

Five-year actuarial survival was 86%. The actuarial breast recurrence rate at
five years was 8% of which 82% were salvaged with mastectomy or repeated wedge
resection. The five-year actuarial survival following breast only recurrence was 59%
and the five-year disease-free survival was 65%.

The results of the Yale experience together with those of the institutions listed in
table 1 demonstrated long term survival following CS+p°RT was comparable to that
achieved with more traditional radical therapy. The retrospective design of these
studies precludes an absolute conclusion but justified randomized prospective trials
comparing the two types of therapy.
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In order to establish CS+p°RT as an alternative treatment for early breast
cancer, five well-designed randomized prospective trials, as summarized in table 2,
were undertaken.3'4 6 35 36 Of these, the National Surgical Adjuvant Breast Project
Protocol B-06 (NSABP B-06) is most representative.6 1,843 patients with clinical
stage I and stage II breast cancer enrolled between April 1976 and January 1984 and
were randomly assigned to one of three groups receiving treatment with either
mastectomy alone, or conservational surgery with or without primary radiotherapy. All
patients underwent axillary dissection. Those with positive nodes received adjuvant
chemotherapy. Radiotherapy was delivered to the breast only to a total dose of 5,0005,300 cGy, without a boost to the tumor site.

Among node negative patients treated with mastectomy, five-year disease-free
survival was 71.9% compared to 81.4% for the CS+p°RT group. Overall, survival
was 81.7% in the mastectomy group and 90.7% in the CS+p°RT group. The five-year
actuarial recurrence rate for patients treated with CS+p°RT was 7% compared to a rate
of 32% in patients treated with conservational surgery alone.

Life table estimates

indicated treatment by conservational surgery, with or without breast irradiation,
resulted in disease-free, distant disease-free and overall survival at five years that did
not statistically differ from that of patients treated with traditional mastectomy. This
study did, however, show a trend towards a longer disease-free and overall survival for
patients treated with CS+p°RT.

Several studies have investigated the cosmetic sequelae of conservative
treatment. Delouche, at the Centre de Charlebourg in Paris, examined 330 patients
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conservatively treated for clinical stage I and II breast cancer and followed for a
minimum of two years.7 In 37.6% of these patients, the treated breast appeared to be
essentially identical to the untreated breast. In 39.1%, minor sequelae of treatment
were apparent, including breast asymmetry, modest subcutaneous induration or skin
changes due to radiotherapy.

More marked changes were noted in 16.7%,

corresponding to significant deformation of the treated breast and 6.7% of the patients
had unacceptable results, representing either a cosmetically unsightly or painful
shrunken breast. Similarly, follow-up of five years for 239 conservatively treated
patients was obtained by the Joint Center for Radiation Therapy (JCRT) at Harvard
University.37 Overall cosmetic results were found to deteriorate for the first three years
following therapy, after which they stabilized. At five years overall cosmetic results
were judged as excellent (little or no change) in 77% of patients, good (minimal, but
identifiable changes) in 9%, fair (significant results of radiation therapy noted) in 9%,
and poor (severe normal tissue sequelae) in 5%. Poor cosmesis was related to extent of
surgery, with patients undergoing more extensive excisions having poorer results and
total dose of radiation, with a total dose greater than 5,000 cGy being associated with
greater degrees of fibrosis and retraction.

Additional complications of conservative treatment are those experienced during
primary irradiation of the treated breast. Acute complications include fatigue, irritation
and erythema of the skin. These are self-limited, usually resolving within several
weeks of treatment. Significant long term complications are unusual.

The JCRT

reports rib fractures as the most common (5%) followed by cosmetically significant arm
edema (4%), radiation pneumonitis (2%) and rarely, paresthesias or brachial plexus
disorders.37
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In 1990, with strong support for the use of conservative treatment for early
breast cancer, a panel of experts convened to provide consensus recommendations for
conservative surgical treatment techniques and patient selection criterion.38 The major
criterion for patient selection is feasibility of resecting the primary tumor without major
cosmetic deformity. Patients not considered appropriate candidates include those with
two widely separated primary tumors in the same breast and patients whose
mammography reveals diffuse micro-calcifications. Surgical removal of the tumor
should be performed to achieve grossly negative margins of resection with verification
of microscopically free margins determined on permanent histologic sections after
inking of the specimen’s borders. Further resection in the case of positive margins is
recommended.

Axillary dissection, (levels 1-2), provides valuable prognostic

information for patients with primary breast cancer and may be routinely employed. It
is recommended the entire breast be irradiated to a total dose of 4,500-5,000 cGy, with
a boost delivered to the region of the tumor to doses of 1,000-1,500 cGy. It is noted,
higher doses of radiation may result in an unacceptable degree of fibrosis and
retraction. Future research aimed at refining existing prognostic factors and identifying
subgroups most likely to benefit from further adjuvant therapy is encouraged.

LOCAL RECURRENCE IN CONSER VA TIVEL Y TREA TED PA TIENTS

Having established CS+p°RT as an option for the treatment of early breast
cancer, data accumulated from retrospective and prospective studies was analyzed to
define the natural history of breast cancer treated with conservative therapy. One initial
conclusion derived from such analyses was that local recurrence in conservatively
treated patients occurred over a protracted time interval. Unlike patients treated with
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mastectomy, most of whom recur within three years, conservatively treated patients are
at constant low risk of recurrence for many years following their initial treatment.39 A
collaborative study, conducted at the Princess Margaret Hospital, the Institut Curie and
the Marseilles Cancer Institute, demonstrated a constant risk of local recurrence over a
fourteen year period.12 In the Yale series, the breast recurrence rate at five years was
8%, consistent with the 1-2% annual risk of recurrence reported by most institutions.5
Table 3 summarizes the long risk periods reported for conservatively treated patients.

The continued risk of local recurrence in conservatively treated patients
reinforces the need to emphasize rigorous follow-up, as patients treated with breast
preserving therapy retain breast tissue at risk for developing a second primary tumor or
a recurrence of the original tumor from residual malignant cells which survived the
initial treatment.

Since the majority of local recurrences in conservatively treated patients occur at
or near the primary site, most are probably recurrences of the primary tumor. 67% of
the recurrences in the Yale series occurred at the same site, defined as at or near the
original primary site, while 33% were observed elsewhere in the breast.5 Analysis of
recurrences in the JCRT series, after four and a half years of follow-up, revealed 57%
occurring directly at the site of the primary, 33% occurring at the edge of the boosted
volume and 10% occurring elsewhere in the breast.40 Similarly, the Marseille group
reported 79% of their recurrences occurring in the vicinity of the primary tumor bed but
noted that with longer times to recurrence, an increasing percentage were found
elsewhere in the breast.41 Based on such observations, they have suggested that
tumors recurring late should be considered second primary tumors.
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Pathological examination of recurrences undertaken by the JCRT and the
NSABP B-06 project, noted identical or similar histologies among nearly all primaries
and local recurrences found at or near the original site.17 42 Review of primary and
recurrence material from the 24 local recurrences treated at Gustave-Roussy revealed in
all cases unchanged histological subtype and little or no change in tumor grade.13

FACTORS PREDICTING LOCAL RECURRENCE IN CONSERVATIVELY
TREA TED PA TIE NTS

Extensive efforts have been made to identify factors which can predict which
patients will have a high risk of local recurrence following conservative treatment.811,13.41,43-46 To

date, these predictive factors fall into two categories: factors related to

tumor burden and factors related to intrinsic tumor biology.

Conservational therapy aims to preserve the cosmetic appearance of the
cancerous breast; therefore, it is conceivable that micro-foci of malignant cells remain in
the affected breast after tumor excision.

In this case, the primary radiotherapy

employed after excision should help eliminate the remaining tumor cells. Extent of
initial conservational surgery and degree of intra-ductal carcinoma in the primary, as
well as the dosage and timing of primary irradiation and other clinical and pathological
factors have been reported as prognostic of local recurrence.

Patients in the JCRT series having a less-than-excisional biopsy of their primary
suffered a higher percentage of local recurrence than those undergoing complete
excisional biopsy (35% vs 7%).40 When primary tissue from patients suffering local
failure in the JCRT series was histologically analyzed, tumors noted to have an
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extensive intra-ductal component, (EIC), (considered present when intra-ductal
carcinoma occupied 25% or more of the area encompassed by the infiltrating tumor and
was present in random sections of grossly unremarkable breast tissue or clearly
extended beyond the infiltrating edge of the tumor into surrounding breast tissue) were
associated with a substantially increased risk for local failure after ten-years of follow¬
up. Patients without EIC experienced a 3% failure rate at ten-years compared to a 35%
failure rate for those with EIC.45 However, several groups, including Yale and the
Institut Gustave-Roussy, have failed to demonstrate a similar predictive value for EIC,
while the Institut Curie found EIC slightly correlated with increased local recurrence but
also associated with better survival.13 37

Patients experiencing local recurrences in the Institut Gustave-Roussy series
were analyzed for thirty variables related to breast relapse.13 Two of the three factors
correlated with local recurrence were duration of radiation treatment and time interval
between tumor excision and initiation of radiotherapy. Patients whose treatments were
delivered in less than six weeks and those who experienced a delay of more than seven
weeks between initial biopsy and radiotherapy had a greater risk of local failure.

Analysis of JCRT data revealed the risk of recurrence at the site of the primary
was related to the dose of radiation given to the primary site.40 Recurrences at the
original site were rare in patients receiving doses greater that 6000 cGy. Thus, as
dosage of radiation increases and interval to treatment following initial biopsy is
shortened, the tumor burden remaining after surgery is presumed to be more effectively
eliminated and risk of local recurrence diminished.
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The Yale series demonstrated patients with positive axillary nodes had a lower
rate of local recurrence.48 These patients also tended to be younger, have larger
primaries and more aggressive tumor histologies. Given these negative prognostic
factors, one would have expected these patients to have a higher local recurrence rate.
Instead, they fared better than their node-negative counterparts. It is speculated this
may be related to the fact that 88% of node-positive patients in the Yale series received
adjuvant systemic therapy in contrast to 8% of the node-negative patients. Here again,
the use of adjuvant therapy, in this case chemical and/or hormonal, theoretically
eliminated the residual tumor burden following conservative therapy, thereby reducing
the risk of local recurrence.

Factors related to tumor aggressiveness have also been associated with the risk
of local failure. The NSBABP B-06 analyses showed high nuclear grade associated
with increased risk for local recurrence.49 In the JCRT series, grade 3 tumors were
associated with higher percentages of local failure.50 The Marseille Risk Factor study
showed mononuclear cell reaction, a marker of aggressive tumor growth, and high
histologic grade were predictors of local failure.11 The need for more accessible and
easily reproducible measures of biological aggressiveness, such as DNA-FC analyses
or measurements of growth fractions with monoclonal antibody techniques, is
proposed. To date, only microscopic examination of tumor specimens can be used to
assess risk of local failure secondary to tumor aggressiveness in conservatively treated
patients.11

PROGNOSIS FOLLOWING LOCAL RECURRENCE

Prognosis following local recurrence for patients treated with conservative
therapy differs from that of patients treated with mastectomy.

33-50% of patients

experiencing chest wall recurrence after mastectomy have concurrent distant metastases.
In contrast 9-25% of patients experiencing local failure following conservative
treatment have concurrent distant disease.16 Patients who recurred in the chest wall
after mastectomy and subsequently received radiation therapy where followed by the
Joint Center at Harvard. Five-year disease-free survival in this group was 30% and
decreased to 7% at ten years.16 This trend is confirmed by several studies which report
survival following chest wall recurrence in patients treated with primary mastectomy
ranges from 21-36% at five years and 5-26% at ten years.5154 In contrast, various
studies report five-year disease-free survival following local recurrence in
conservatively treated patients between 59-84% and ten-year disease-free survival
ranging from 50-65%.1215 Researchers at the Institut Gustave-Roussy and Princess
Margaret Hospital failed to demonstrate any difference in overall survival between
conservatively treated patients who experienced local failure and those who had never
had a local recurrence.13-55 Table 4 provides survival data following local recurrence
from several representative series.

The optimal treatment for patients who experience local recurrence following
conservative therapy is not yet known. Currently, most patients undergo salvage
mastectomy, although in some cases further conservative treatment is employed.16 To
date, the role of adjuvant chemotherapy and hormonal therapy in this population
remains undefined.
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To aid in the management of patients experiencing local recurrence after
conservative therapy, efforts have been made to find reliable predictors of prognosis
following failure. Currently available prognostic indicators are limited to clinical
observations. Those most consistently reported are time to recurrence, extent and site
of recurrence and histology of recurrence.

In the Yale series, patients recurring four or more years after primary treatment
had a significantly better prognosis than patients recurring sooner.20 Similarly, patients
treated in the Marseille series were found to have a favorable prognosis (84% survival
at five years) if they recurred five or more years after primary treatment.41 At the
Institut Curie, recurrences occurring within three years after primary therapy were more
often associated with concurrent nodal involvement and distant metastases and, as a
result, poorer prognosis.20 The University of Pennsylvania series demonstrated a
statistically insignificant trend towards poorer prognosis among early recurrences.15
The JCRT failed to show any difference in survival among patients who recurred after
two or more years compared to those recurring in less than two years.16

Various measures assessing qualitative features of locally recurrent tumors have
been predictive.15-16-20'41 Site and extent of local recurrence was predictive in the Yale
series.20 Localized tumors, recurring elsewhere in the breast and measuring less than 3
cm, were associated with a better prognosis. Similar findings have been reported by
the University of Pennsylvania, Marseille and Gustave-Roussy.1315 41 Others have
failed to demonstrate the prognostic value of these indicators.16
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Examination of histologic features of recurrent tumors has not been uniformly
helpful in predicting outcome.

In the JCRT series, patients with purely or

predominantly non-invasive recurrent tumors suffered no further recurrences, whereas,
38% of patients with predominantly infiltrating tumors, experienced some further
recurrence.16 Histology of the recurrent tumor, assessed somewhat differently, was
not prognostic in the Yale series.20

PROGNOSTIC INDICA TORS USED FOR PRIMAR Y BREAST CANCER

At best, currently available data provides a number of clinical observations
which can be associated with prognosis following local recurrence in the conservatively
treated patient.

Histologic features of the recurrent tumor are the only objective

measures available, but data examining this potential predictor is scarce, inconclusive
and hindered by potential problems of reproducibility.

In contrast, prognosis for

patients with primary breast cancer has been successfully predicted using a number of
quantitative as well as qualitative factors.

The Surveillance, Epidemiology and End Results (SEER) program of the
National Cancer Institute has followed 24,740 breast cancer patients through tumor
registries in five states.56 The results of this study indicate size of primary and lymph
node status are independent but additive prognostic indicators for primary breast
cancer.

As tumor size increases, survival decreases regardless of nodal status.

Likewise, as nodal involvement increases, survival status decreases regardless of tumor
size. Patients with primaries less than 2 cm in diameter and negative lymph nodes have
the most favorable prognosis with 96.3% five-year survival whereas patients with
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primaries larger than 5 cm and positive axillary nodes have a survival at five years of
only 45.5%.

In addition to clinical measures of prognosis, several quantitative measures have
proven to be valuable indicators of prognosis in primary breast cancer.

Steroid

hormone receptor status has well established independent predictive value.57 In
patients with negative lymph nodes, positive estrogen receptor status is associated with
a better overall and disease-free survival. For patients with positive nodal involvement
progesterone receptor status is a strong prognosticator.58 In this case, lymph node¬
positive patients with positive progesterone receptor status have a better disease-free
survival than their progesterone receptor negative counterparts.

Currently evolving quantitative prognostic indicators for primary breast cancer
include measures of DNA content and cellular proliferation, obtained using techniques
of DNA-FC.27 Overall, tumors with DNA values within the limits of normal tissue
correlate with favorable prognosis while tumors with high proliferative indices are
associated with poor outcome.2126-28'30

TECHNIQUES OF CELL ANAL YSIS USING DNA FLOW CYTOMETR Y

While tumor cell proliferation can be measured by both the histologically
derived mitotic index and the autoradiographically derived thymidine labeling index, the
technique of DNA-FC provides rapid measurement of cell proliferation without the
constraints of fresh tissue or labor intensive histologic analyses. In addition, measures
of DNA content are concurrently obtained with DNA-FC analysis. Thus, DNA-FC
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analysis of fresh or archival tumor cells allows direct measurement of DNA content
(DNA-ploidy) and indirect measurement of tumor cell proliferation (S-phase fraction,
SPF). When the measured DNA content of tumor cells is equal to that found in normal
cells the tumor is defined as DNA-diploid. If the DNA content is either greater or less
than normal, the tumor is defined as DNA-aneuploid.

Hedley developed the technique for analyzing paraffin-embedded archival tissue
with DNA-FC after observing the impressive degree of cellular preservation in paraffinembedded tissue slices which were dewaxed and rehydrated.59 Once archival tumors
cells are rehydrated, they are processed in a manner similar to that previously
established for cytometric analysis of fresh tissue. Intact tumor cells are treated with a
digestive enzyme, such as trypsin or pepsin, with subsequent tumor lysis. The freed
cellular nuclei are then tagged with an appropriate DNA fluorochrome and run through
the DNA flow cytometer.

The flow cytometer has four components: a light source, usually a laser, a
sample chamber and optical assembly, a set of associated electronics that convert light
impulses to digital signals and a computer system that controls instrument operations,
collects data and performs analytical routines.60 Once a cell sample is prepared, it is
added to the sample chamber and at a rate of approximately 10,000 cells per second,
passes single file past the light source. As cells pass the laser, light is scattered in all
directions. Light which is deflected forward is referred to as forward angle light scatter
(FALS) and is directly proportional to the size of the passing particle, assuming the
particle is a homogeneous sphere. Light which is orthogonally deflected is referred to
as 90 degree light scatter (90°LS). It is reflected from internal cellular structures and is

indicative of cell granularity. Fluorescent emissions from DNA specific probes excite
the system’s lasers and generate histograms from which the DNA content of resting and
dividing cell populations is determined. The DNA flow cytometric histogram from a
normal cell population will contain a single G0/G1 peak representing most of the
sample’s cells in the resting phase of the cell cycle. Smaller peaks will be generated by
cells in the proliferative G2/M and S-phases.

A cell population is defined as DNA-aneuploid if it has two or more G0/G1
peaks with the second being at least 10% of the first.61 DNA index is the calculated
ratio of the abnormal G0/G1 peak to the normal G0/G1 peak. Cell cycle analysis
computer programs divide DNA histograms into their constituent parts of G0/G1,
G2/M and SPF by assessing the relative distribution of DNA. Representative DNAdiploid and DNA-aneuploid histograms appear in figures 1 and 2 respectively.

THE USE OF DNA FLOW CYTOMETRY AS A PROGNOSTIC INDICATOR
FOLLOWING LOCAL RECURRENCE
Measures of DNA content and cellular proliferation are valuable prognostic
indicators for a number of solid and non-solid tumors.62 Methods have been
successfully developed to apply DNA-FC analysis on paraffin-embedded archival
tissue.

The reproducibility and correlation between data derived from fresh and

archival tissue has been verified by Hedley and others.59-63 68

Applying this

technology to the readily available archival tissue obtained from patients who
experienced local recurrence in the Yale series should provide an indication of the
prognostic value this measure holds for this population.

17

Methods and Materials

PA TIENTS

433 patients with primary clinical stage I and stage II breast cancer were treated
with conservational surgery and primary irradiation at the Yale-New Haven Hospital
between January 1962 and December 1984. Clinical staging was in accordance with
the guidelines of the American Joint Committee/ Union Internationale Contre Le
Cancer. Conservational surgery involved excisional biopsy of the breast lesion with no
specific attempt made to obtain microscopically free surgical margins, although the
surgical specimen generally contained a rim of normal breast tissue around the tumor.
Axillary dissection was not routinely performed. Most patients did not receive adjuvant
systemic therapy although multi-agent chemotherapy or hormonal therapy was used in
some patients with pathologically positive nodes.

Radiation therapy was delivered using 4-6 MeV linear accelerators with
tangential fields directed at the breast with an electron boost to the tumor bed to a total
median dose of 6400 cGy.

Radiation was delivered in 200 centigrade per day

fractions. Wedges were routinely employed to optimize dose homogeneity throughout
the breast tissue.

The regional nodes were treated in the majority of patients. In patients not
undergoing axillary dissection, the internal mammary, supraclavicular and axillary
nodes were irradiated.

Internal mammary nodes were irradiated with alternating

photons and 13 MeV electrons with a separate field to a total median dose of 4600 cGy
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specified at a depth of 3 cm. Occasionally the internal mammary nodes were included
in the tangential fields. Supraclavicular and axillary nodes were treated with a separate
half-blocked anterior field angled 10-15° off of the spinal cord. The field extended
medially from the midline angled off the spinal cord and cleared the entire axillary
contents laterally.

In patients undergoing axillary dissection, the internal mammary chains and
breast were treated as described above. The supraclavicular field, however extended
only from the midline to approximately the medial border of the humeral head laterally,
thus sparing the lower axillary contents in both node positive and node negative
patients. Radiation treatment was delivered over a six to seven week period. Figure 3
schematically represents these treatment policies.

Patients were seen in follow-up by both the radiation oncologist and referring
surgeon at three to six month intervals. Routine mammograms and chest X-rays were
performed annually. Follow-up liver scans and bone scans were not performed unless
clinically indicated. Disease and survival status for each patient is routinely updated
with documented follow-up visits, correspondence with the patient and her surgeon or
internist and through data available from state tumor registries.

Charts were retrospectively reviewed in an effort to document all patients
experiencing local recurrence.

50 patients experienced recurrent tumor in the

conservatively treated breast prior to June 1990. An effort was made to obtain tissue
samples from the recurrent breast tumors of these patients. Tissue could be retrieved
for 76% of the recurrent tumors.
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DMA FLOW CYTOMETRY

DNA-FC analysis was carried out on all available tissue samples.

Cell

preparation was carried out as follows. 50 pm sections were obtained from each
paraffin-embedded sample. An additional 6 pm cut was made from each section and a
slide prepared to verify the presence of tumor cells in each section. Sections were
deparaffinized with Americlear solution, followed by stepwise hydration in ethanol
(100%, 95%, 70%,50%) and distilled water. Cells were then treated with pepsin and
lysed. Nuclear material was tagged with propidium iodide and analyzed with an Epics
Profile flow cytometer (Coulter Electronics Inc.) using 488 nm excitation.

Both

forward and 90 degree light scatter gates were used to exclude debris signals. DNA
index and cell cycle distribution were calculated using the Modfit software program.
The mean coefficient of variation for the entire sample was 5.6 (median 5.2).

ST A TISTICAL ANAL YSIS

Statistical analyses were performed employing the PRODAS statistical package from
Conceptual Software Inc. on a Zenith 386 IBM compatible computer. The significance
of survival differences between patient groups was calculated according to the Cox Life
Table and Survival Analysis Model.

The Cox Life Table Regression Model was

employed for univariate analyses.
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Results

PA TIENT POPULA TION

As of January 1990, 433 patients, with a minimum follow-up of five years and
a median follow-up of 8.21 years, have received conservative treatment at the YaleNew Haven Hospital. Characteristics of the treated population appear in table 5. The
median age of treated patients is 55.0 years (range, 20-89 years). 70% were treated for
clinical stage I breast cancer.

43% underwent axillary dissection.

9% received

adjuvant hormonal therapy and 12% received adjuvant chemotherapy. The overall fiveyear actuarial survival rate for the population is 0.86 ± 0.02, the actuarial five-year
disease-free survival rate is 0.82 ± 0.02.

PATIENTS WITH LOCAL RECURRENCE

Patient status, as of January 1990, appears in table 6. 82% of patients in the
entire population remain alive. 50 patients have experienced local failure with a fiveyear actuarial breast recurrence rate of 0.08 ± .02. 44 of the recurrences were confined
to the breast, 6 patients had coincident distant disease. Follow-up is available for a
median of 5.06 years following recurrence.

Flow data was obtained from 100% of available tissue samples.

Recurrent

tumor tissue was available for 38 patients (76%). Patients for whom tumor tissue is
available do not differ significantly from the total recurrent population in terms of age,
original clinical stage, original nodal status, mode of recurrence detection, interval to
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recurrence, site of recurrence, extent of recurrence, adjuvant therapy, salvage therapy
and disease status (table 7).

Figures 4 and 5 depict actuarial curves of overall and disease-free survival for
all patients experiencing local recurrence and for patients with available flow data.
Median follow-up post-recurrence for patients with flow data is 5.8 years. For all
recurrences the Five-year actuarial survival post-recurrence is 59% and five-year
actuarial disease-free survival post-recurrence is 65%. For patients with available flow
data, overall actuarial survival Five-years following recurrence is 48%.

Actuarial

disease-free survival for patients with available flow data is 58% at Five-years following
recurrence.

Univariate analysis shows extent of recurrence and time to recurrence are
predictive for Five-year disease-free survival among the patients with available recurrent
flow data (p = 0.000 and 0.007 respectively). Extent of recurrence predicts overall
survival in this group (p = 0.005), while time to recurrence approaches statistical
significance (p = 0.06).

DNA-PLOIDY

Most recurrent tumors (62.8%) were DNA-diploid. Univariate analysis, using
the Cox Life Table Regression Model, shows DNA-ploidy is predictive of overall
survival and disease-free survival Five-years after local failure (p=0.015 and p=0.028,
respectively). Overall actuarial survival, calculated according to the Cox Life Table and
Survival Model, at five-years post recurrence is 63.0% in patients with DNA-diploid
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tumors and 14.9% in patients with DNA-aneuploid tumors. Actuarial curves depicting
overall survival appear in figure 6. DNA-ploidy, calculated by Chi-square analysis, is
positively correlated with distant disease progression (p < 0.05). 46% of patients with
DNA-aneuploid tumors remain distant disease-free, whereas, 76% of patient with
DNA-diploid tumors are free of distant disease progression (table 8).

S-PHASE FRACTION

The median SPF for the sample was 13.8. An SPF value of less than to 12 was
used to define tumors with a low proliferative index. 35% of patients had a tumors
with a low proliferative index. When subjected to univariate analysis, favorable
proliferative index was found to be predictive of overall survival at five-years post
recurrence (p=0.01) as well as disease-free survival at five-years post recurrence (p =
0.0002).

Overall, actuarial survival five-years post recurrence is 82.6% in patients

with low SPF tumors and 24.0% in patients with high SPF tumors. Actuarial diseasefree survival five-years post recurrence is 100% in patients with low SPF tumors and
32.1% in patients with high SPF tumors. Actuarial curves depicting this data are
presented in Figures 7 and 8.
progression, (p <0.01).

SPF is positively correlated with distant disease

56% of patients with high SPF tumors have had distant

disease progression while, 100% of the patients with low SPF tumors remain distant
disease free (table 8).
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COMBINED DNA-PLOIDY AND S-PHASE FRACTION

The results of the separate analyses of patients according to DNA-ploidy and Sphase were combined to create classifications of tumors with favorable and unfavorable
flow profiles. Tumors with a favorable flow profile are defined as DNA-diploid with a
SPF less than 12.

Those with an unfavorable flow profile are defined as DNA-

aneuploid or DNA-diploid with an SPF greater than 12.

13 patients (30%) had

favorable flow profiles. Univariate analysis shows favorable flow profile is predictive
of overall survival five-years post recurrence (p=0.03) and disease-free survival fiveyears post recurrence (p=0.00005).

Overall actuarial survival five-years after

recurrence is 60% for patients with a favorable flow profile and 24% for patients with
an unfavorable flow profile (figure 9). Actuarial disease-free survival five-years after
recurrence is 100% for patients with a favorable flow profile and 36% for patients with
an unfavorable flow profile (figure 10).

Distant disease progression is positively

correlated with flow profile (p < 0.01). 52% of patients with unfavorable flow profiles
had distant disease progression, whereas, 100% of patients with

favorable flow

profiles remain free of distant disease (table 8).

The distribution of previously established post-recurrence prognostic indicators
among patients with favorable and unfavorable flow profiles appears in table 9. The
clinical predictors of prognosis, interval to recurrence, site of recurrence and extent of
recurrence are all positively correlated with flow profile.

24

Discussion

Local recurrence in the conservatively treated patient is associated with a
prognosis more favorable than that of a patient who has suffered local failure following
primary treatment with mastectomy. Following salvage mastectomy, approximately
50% of these patients will remain disease-free and 50% will succumb to progressive
disease. Measures of recurrent tumor DNA content and proliferative index obtained
through DNA-FC appear to be predictive indicators in this population of patients.

When compared to patients with DNA-diploid recurrences, patients with DNAaneuploid tumors have shorter overall and disease-free survival. This parameter has
not been systematically measured in patients experiencing local failure following
conservative treatment.

Its prognostic value for primary breast cancer is widely

reported.23'26 28’30-65 Beerman performed DNA-FC on fresh and archival tissue from
690 patients with stage I-III breast cancer followed for a median of seven years and
observed that DNA-aneuploidy was associated with shortened overall and disease-free
survival.30 Coulson looked at 74 patients with a median follow-up of three years and
found 92% of deaths occurring within three years were in patients with DNA-aneuploid
tumors.26 Others have failed to demonstrate the prognostic value of DNA-FC when
measuring DNA-ploidy alone.29 69 Toikkanen’s retrospective examination of tissue
from 115 stage I-II breast cancer patients with a median follow-up of twenty-seven
years failed to demonstrate any influence on survival with respect to DNA-ploidy.29
Similarly, Rofagha’s examination of archival tissue from 165 patients with node¬
negative breast adenocarcinoma, followed for a median of eight years, did not show
prognostic significance for measures of DNA ploidy. 69
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Measures of S-phase fraction alone were highly significant predictors of overall
and disease-free survival. Using the institutionally accepted cut-off of 12%, patients
with low SPF had longer overall and disease-free survival. S-phase fraction has not
been previously examined as a prognostic indicator following local recurrence in
conservatively treated breast cancer but its utility as a prognostic indicator in primary
breast cancer is well documented

21,23,65

Using 9% as a cut off for low SPF,

Hatschek measured SPF in the primary tumors of 15 patients who experienced local
failure. The patients’ initial staging and mode of treatment were not reported. High
SPF was associated with an increased, but not statistically significant, risk of
recurrence but did significantly correlate with length of survival following
dissemination of disease.24

DNA-ploidy and S-phase fraction both independently predict outcome
following local recurrence.

Information derived from these two parameters was

combined to assign patients to favorable and unfavorable groups.

Patients with

’’favorable” flow profiles (DNA-diploid, SPF < 12) had significantly longer overall and
disease-free survival. This is in agreement with studies in patients with primary breast
cancer, which have assigned patients to prognostic groups by combining measures of
DNA-ploidy and SPF.22 23 Clark’s examination of breast tissue from 345 node¬
negative patients with a median follow-up of 4.9 years showed that overall and diseasefree survival was longest in patients with DNA-diploid, low SPF tumors.22
Kallioniemi applied a prognostic index which includes DNA index and S-phase fraction
to 294 stage I-III breast cancer patients and found that it correlated with overall
survival.23
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In order to apply data derived from DNA-FC to clinical practice, the reliability
of these measures must be considered.

The established ’’gold-standard” for

measurement of cell proliferative indices is tritiated thymidine labeling (TLI). This
autoradiographic technique cannot be practically applied on a large scale because it is
time consuming, expensive and requires fresh tissue. Nonetheless, its value as a
powerful independent prognostic indicator in primary breast cancer is strongly
supported in the literature.27 DNA-FC provides information on both DNA content and
proliferative index and offers the advantage of rapid tissue analysis which can be
performed on fresh or archival tissue. Costa and McDivitt report a positive correlation
between S-phase values obtained by DNA flow cytometry and those obtained by
tritiated thymidine labeling.67 70 Kallioniemi’s comparison of fresh and paraffinembedded tumors showed S-phase fractions from both tissue types were positively
correlated.64

Technical difficulties associated with flow cytometric analysis of paraffinembedded tissue raise concern about the accuracy of its determinations. Analysis of
paraffin-embedded tumors is usually associated with a larger coefficient of variation
representing larger proportions of cellular debris in the tissue sample. This raises the
concern that some near DNA-diploid tumors are misclassified as DNA-diploid. Hedley
looked at 233 frozen tissue samples and compared them to 280 paraffin-embedded
breast tumors with similar pathological staging and found the paraffin samples had a
higher proportion of tissues with a DNA index of 1.0 (DNA-diploid). Yet, his
comparison of 24 frozen and paraffin-embedded samples from the same tumor yielded
identical proportions of near DNA-diploid tumors.65
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The reliability of SPF measures derived from paraffin-embedded tissue has also
been called into question.64 In the case of DNA-aneuploid tumors, overlapping cellcycle distributions create technical difficulties in determining S-phase fraction which, in
contrast, is usually readily evaluable in DNA-diploid tumors. However, in DNAdiploid tumors interpretation of SPF is difficult because the cell-cycle distribution
represents both tumor and non-tumor cells.

Kallioniemi demonstrated greater

intratumor variation in SPF measures derived from DNA-diploid tumors and concludes
this results from cytometrically indistinguishable populations of tumor and non-tumor
cells in a DNA-diploid tissue sample.64

He notes, however, that the extent of this

problem can be reduced by carefully selecting for analysis only those tissue sections
which contain large numbers of tumor cells.

Despite these potential technical

limitations, DNA-ploidy and S-phase fraction determinations have been consistently
correlated with outcome in primary breast cancer.

The implications of the data presented in this study rest in its potential role as a
guide for the clinical management of patients experiencing local recurrence following
conservative treatment for early stage breast cancer. Unlike primary breast cancer, for
which the well defined prognostic indicators of stage, lymph node and receptor status
are used to guide treatment, few prognostic indicators are available to help guide the
management of patients experiencing local failure following conservative therapy.
Axillary exploration at the time of recurrence is of questionable value. Most patients
undergoing conservative treatment undergo axillary dissection and irradiation at the time
of primary treatment. This makes re-exploration at the time of recurrence a technically
difficult, low yield procedure.

Although retrieval of a positive lymph node may

influence decisions regarding adjuvant systemic therapy, the conclusions derived from
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an absence of involved nodes must remain equivocal, due to the necessarily small
sample likely to be retrieved from a previously dissected axilla.

The prognostic significance of hormone receptor status in this patient population
remains undetermined.

Preliminary analysis of receptor status in the Yale series

suggests patients with recurrent tumors which are estrogen receptor-negative have
poorer survival than patients with estrogen receptor-positive tumors.20 Unfortunately
this data is available for only 33% of the patients experiencing local recurrence.
Determination of receptor status by immunohistochemical staining of paraffinembedded blocks, obtained from the majority of patients experiencing local failure in
our series, is currently underway.

Clinical and pathological variables, including time to recurrence, extent and
location of recurrence and tumor histology, have been shown to be prognostically
significant. Adapting these variables for use as guides for the clinical management of
patients following local failure is hampered by their heavy reliance on observer
judgment and resulting problems of reproducibility due to inter-observer variability. In
contrast, DNA-FC analysis provides readily reproducible quantitative measures which,
in our series, were positively correlated with these previously established clinical
prognostic factors.

The low overall incidence of local recurrence following conservative treatment
for early stage breast cancer results in relatively small numbers of patients available for
study. The accumulation of larger samples with longer follow-up will be necessary to
firmly establish the prognostic significance of DNA-FC analysis for this population.
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When this is achieved, these prognostic factors can be used to design the randomized
prospective clinical trials which will be necessary to determine optimal salvage
treatment and appropriate adjuvant systemic therapy for patients experiencing local
recurrence following conservative treatment.

In summary, DNA flow cytometric measurements of DNA-ploidy and S-phase
fraction in local recurrent tumor tissue may help predict overall and disease-free
survival following local failure in conservatively treated stage I-II breast cancer
patients.

In our sample patients with DNA-diploid, low S-phase tumors had an

excellent prognosis. With further verification of these findings by others with similar
patient populations, the application of this data to the clinical management of patients
experiencing local failure can be anticipated.
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Table 2
Mastectomy vs. Conservative Treatment for Early Stage Breast Cancer — Randomized Prospective Trials
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Table 3
Local Recurrence Rates in Conservatively Treated Early Stage Breast Cancer

Subjects

Follow-up

Breast
Recurrence Rate

GUSTAVE-ROUSSY13

436

5.0 years

7% at five years

MDAH 10

536

5.3 years

9% at five years

JCRT 40

607

6.3 years

9% at five years

YALE 20

433

8.2 years

8% at five years

MARSEILLE 9

1593

11 years

7% at five years

Series

Table 4
Survival Following Local Recurrence in Conservatively Treated Patients

Series

Number
of
Recurrences

Follow-up
Following
Recurrence

Overall Survival
Following
Recurrence

Yale 20

50

5.0 years

59% at five years

JCRT 16

90

2.8 years

69% at eight years

Univ. of Pennsylvania* 15

65

1.6 years

84% at five years

Marseille 14

178

not reported

70% at five years

♦Survival calculated for patients undergoing salvage mastectomy
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Table 5
Patient Population Characteristics
N=433

Characteristic

Frequency

Percentage

AGE
<50 years
>50 years

159
274

37
63

CLINICAL STAGE
Stage I
Stage II

301
132

70
30

PATHOLOGICAL NODAL STATUS
Node-negative
Node-positive
No axilllary dissection

128
57
248

30
13
57

379
54

87
12

393
40

91
9

ADJUVANT THERAPY
Chemotherapy
No
Yes
Hormonal Therapy
No
Yes

*Mean age is 54.0 years (Median 55.0 years).
Mean follow-up is 9.1 years (Median 8.21 years)
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Table 6
Patient Status as of January 1990
N=433

Frequency

Status

ALIVE
DEAD

Percentage

356

82

77

18

44
6
12
47

10
13
11
3

FAILURE
Treated breast alone
Treated breast with distant metastases
Lymph nodes
Distant metastases
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Table 7
Comparison of Characteristics of All Patients Experiencing Local
Recurrence and Those with Flow Data Available

Characteristic

All Recurrences
N=50

Recurrences with
Flow Data
N = 38

frequency

%

frequency

%

P

25
25

50
50

14
24

37
63

NS

37
13

74
26

28
10

74
26

NS

Node-negative
Node-positive
Unknown
MODE OF DETECTION
Physical exam only
Mammography only
Physical exam and mammography
Physical exam, mammography negative
SALVAGE THERAPY

13
9
28

26
18
56

8

21
18
61

NS

7
23

19
14
14
3

38
28
28
6

16
10
10
2

42
26
26
5

NS

Modified radical mastectomy
Simple mastectomy
Lumpectomy
Biopsy
INTERVAL TO RECURRENCE

21
18
7
4

42
36
14
8

15
14
4
4

39
37
10
10

NS

< 4 years
> 4 years
SITE OF RECURRENCE
Same site
Elsewhere
EXTENT OF RECURRENCE
Localized
Diffuse
ADJUVANT THERAPY
Chemotherapy
Hormonal therapy
None
DISEASE STATUS
Alive, No Evidence of Disease
Alive, with Disease
Dead, No Evidence of Disease
Dead, with Disease

24
26

48
52

19
19

50
50

NS

36
14

72
28

28
10

74
26

NS

38
12

76

28
10

74
26

NS

15
8
27

30
16
54

11

29
21
50

NS

27
5

54
10
4
32

44
13
5
37

NS

AGE AT DIAGNOSIS
<50 years
>50 years
CONICAL STAGE
Stage I
Stage 13
ORIGINAL PATHOLOGICAL NODE STATUS

2
16

37

24

8
19
17
5

2
14

Table 8
Frequency of Distant Disease Progression by Flow Parameters at Recurrence
N=38

Flow Parameters

No Distant Disease

Distant Disease
Progression

frequency

%

frequency

%

P

DNA-PLOIDY
DNA-Diploid
DNA-Aneuploid

19
6

76
46

6
7

24
54

p < 0.05

S-PHASE FRACTION
SPF < 12
SPF > 12

15
10

100
43

0
13

0
57

p < 0.01

FLOW PROFILE
Favorable (D, <12)
Unfavorable

13
12

100
48

0
13

0
52

p < 0.01
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Table 9
Distribution of Post-recurrence Prognostic Indicators Among Patients with Favorable
and Unfavorable Flow Data*
N=38

Characteristic

INTERVAL TO RECURRENCE
< 4 years
> 4 years
SITE OF RECURRENCE
Same site
Elsewhere
EXTENT OF RECURRENCE
Localized
Diffuse

Favorable Flow
Profile
N= 14
frequency
%

Unfavorable
Flow Profile
N = 24
%
frequency

P

3
11

21
79

16
8

67
33

p < 0.01

7
7

50
50

21
3

87
13

p < 0.05

14
0

100
0

14
10

58
42

p < 0.01

* Favorable Flow Profile = Diploid with SPF £ 12
Unfavorable Flow Profile = Aneuploid/Diploid with SPF >,12
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Figure 1
DNA-diploid Histogram
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Figure 2
DNA-aneuploid Flistogram
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Figure 3
Schematic Representation of Radiation Treatment Policy

AXILLARY DISSECTION

NO AXILLARY DISSECTION
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Figure 4

OVERALL SURVIVAL

Survival

All Recurrences vs. Recurrences with Flow Data*

^Actuarial Estimate +/- Standard Error at 5 Years
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Figure 5

DISEASE-FREE SURVIVAL

Disease-free Survival

All Recurrences vs. Recurrences with Flow Data*

*Actuarial Estimate + /- Standard Error at 5 Years
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Figure 6

OVERALL SURVIVAL

Survival

By DNA-ploidy at First Breast Recurrence*

*Actuarial Estimate + /- Standard Error at 5 Years
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Figure 7

OVERALL SURVIVAL

Survival

By SPF at First Breast Recurrence*

*Actuarial Estimate + /- Standard Error at 5 Years
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Figure 8

DISEASE-FREE SURVIVAL

Disease-free Survival

By SPF at First Breast Recurrence*

*Actuarial Estimate +/- Standard Error at 5 Years
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Figure 9

OVERALL SURVIVAL

Survival

By Flow Profile at First Breast Recurrence*

*Actuarial Estimate +/- Standard Error at 5 Years
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Figure 10

DISEASE-FREE SURVIVAL

Disease-free Survival

By Flow Profile at First Breast Recurrence*

‘Actuarial Estimate +/- Standard Error at 5 Years
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